Does vascepa's efficacy change with aspirin use?

Short answer: No. In the major trial that established Vascepa’s CV benefit (REDUCE-IT), the cardiovascular risk reduction from icosapent ethyl 4 g/day was similar whether patients were taking aspirin or not. There was no meaningful interaction showing aspirin use changed Vascepa’s efficacy.

Some context:
- REDUCE-IT enrolled statin-treated adults at high ASCVD risk, many of whom were on low‑dose aspirin; analyses looked at aspirin use at baseline and found the EPA benefit stayed roughly the same across groups.
- The steps to safety: continue aspirin if it’s clinically indicated for you. Vascepa did not require a change in aspirin dosing or a discontinuation for efficacy reasons. If you have bleeding risks or are planning surgery, discuss with your clinician.

If you’d like, I can summarize the trial data or point you to the FDA label language that discusses concomitant aspirin use.